Erkut Borazanci

机构：HonorHealth, Scottsdale Research Institute (United States), Advanced Medical Research Institute, Arizona State University · ORCID：0000-0001-5136-5462

发表论文 323 篇 · 总被引 4576 次 · h-index 27

代表论文

• Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma (2025 · Gastroenterology · 被引 22)
• Abstract LB407: Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (Pts) with metastatic pancreatic adenocarcinoma (mPDAC) (2026 · Cancer Research · 被引 8)
• A randomized phase II trial of gemcitabine, nab‐paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer (2026 · Cancer · 被引 5)
• Confirmatory Clinical Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma (2025 · Current Oncology · 被引 4)
• Cross-platform comparison of gene expression-based cancer molecular subtyping reveals discrepancies with exome capture methods (2025 · npj Precision Oncology · 被引 3)
• Exosomal ALPPL2 and THBS2 as biomarkers for early detection and disease monitoring of pancreatic ductal adenocarcinoma (2025 · British Journal of Cancer · 被引 3)